
SOMERVILLE, Mass., Oct. 08, 2026 (GLOBE NEWSWIRE) -- DeepHealth, Inc., a global leader in AI-powered health informatics and a wholly owned subsidiary of RadNet, Inc. (NASDAQ: RDNT), today announced new findings published in European Radiology supporting that AI applications within DeepHealth's Prostate MR Solution1 could help clinicians decide more confidently which men may need a prostate biopsy, particularly when MRI findings are uncertain.2 Prostate cancer is the second most commonly diagnosed cancer among men worldwide, with an estimated 1.55 million new cases in 2024.3 MRI helps clinicians assess whether prostate cancer may be present, but some findings remain uncertain.4 A biopsy involves collecting small tissue samples to check for cancer and, if found, assess its grade.










